小RNA
多发性硬化
神经科学
癌症研究
生物
细胞生物学
免疫学
医学
遗传学
基因
作者
Yun-Ji Lim,Sang-A Park,Dandan Wang,Wenwen Jin,Wai Lim Ku,Dunfang Zhang,Junji Xu,Liliana Catherine Patiño,Lei Zhu,Weiwei Chen,Rida Kazmi,Keji Zhao,Ying E. Zhang,Lingyun Sun,WanJun Chen
出处
期刊:Cell Reports
[Elsevier]
日期:2024-07-30
卷期号:43 (8): 114565-114565
标识
DOI:10.1016/j.celrep.2024.114565
摘要
Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of the skin and multiple vital organs, but the immunological pathogenesis of SSc remains unclear. We show here that miR-19b promotes Th9 cells that exacerbate SSc. Specifically, miR-19b and interleukin (IL)-9 increase in CD4+ T cells in experimental SSc in mice induced with bleomycin. Inhibiting miR-19b reduces Th9 cells and ameliorates the disease. Mechanistically, transforming growth factor beta (TGF-β) plus IL-4 activates pSmad3-Ser213 and TRAF6-K63 ubiquitination by suppressing NLRC3. Activated TRAF6 sequentially promotes TGF-β-activated kinase 1 (TAK1) and nuclear factor κB (NF-κB) p65 phosphorylation, leading to the upregulation of miR-19b. Notably, miR-19b activated Il9 gene expression by directly suppressing atypical E2F family member E2f8. In patients with SSc, higher levels of IL9 and MIR-19B correlate with worse disease progression. Our findings reveal miR-19b as a key factor in Th9 cell-mediated SSc pathogenesis and should have clinical implications for patients with SSc.
科研通智能强力驱动
Strongly Powered by AbleSci AI